Clinical Trial Diversity Measures Primed For Inclusion In US FDA User Fee Legislation
Executive Summary
House subcommittee hears testimony on merits of various proposals to increase diversity of clinical trial participants; whether lawmakers ultimately favor measures that impose enforceable obligations on sponsors, or merely incentivize more diverse enrollment, remains to be seen.